Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia

Current Opinion in Oncology

Volumn 19, Issue 6, 2007, Pages 660-666

  Valcárcel, David ^a,b   Martino, Rodrigo ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Acute myeloid leukaemia; Allogeneic stem cell transplantation; Myelodisplastic syndrome; Reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; MELPHALAN; METHOTREXATE; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; HUMAN; IN VIVO STUDY; MORTALITY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RELAPSE; RETROSPECTIVE STUDY; REVIEW; T CELL DEPLETION; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MEDICAL ONCOLOGY; MYELODYSPLASTIC SYNDROMES; RECURRENCE; RISK; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 34948866766     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f0e188     Document Type: Review

References (33)

1. Cornelissen JJ, Lowenberg B. Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2005; 151-155.
2. Valcarcel D, Martino R, Sureda A, et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005; 74:144-151.
3. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19:2304-2312.
4. De Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104:865-872.
5. Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108:836-846. This large retrospective study from EBMT, showed that 3-year OS and PFS were similar with RIC and SMC; a higher risk of relapse-related death was counterbalanced by a lower NRM in MDS.
6. Blaise D, Vey N, Faucher C, Mohty M. Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2007; 92:533-541. This recent review contains in detail all of the current results published referring to RIC in AML and MDS.
7. Lazarus HM, Rowe JM. Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. Leukemia 2006; 20:1673-1682. This recent review contains in detail all of the current results published referring to RIC in AML and MDS.
8. Niederwieser D, Lange T, Cross M, et al. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Pract Res Clin Haematol 2006; 19:825-838. This recent review contains in detail all of the current results published referring to RIC in AML and MDS.
9. Storb R. Can reduced-intensity allogeneic transplantation cure older adults with AML? Best Pract Res Clin Haematol 2007; 20:85-90. This recent review contains in detail all of the current results published referring to RIC in AML and MDS.
10. Scott BL, Sandmaier BM. Outcomes with myeloid malignancies. Hematology Am Soc Hematol Educ Program 2006; 381-389. This recent review contains in detail all of the current results published referring to RIC in AML and MDS.
11. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20:1661-1672. This recent review contains in detail all of the current results published referring to RIC in AML and MDS.
12. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912-2919.
13. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20:128-135. This single center study compared SMC with RIC in patients with MDS or AML. No differences were founnd in major outcomes suggesting that graft-versusleukemia may be more important that conditioning in preventing relapse.
14. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24:444-453. This multicenter study with a large number of patients showed the results of one of the most common used RIC in patients with AML.
15. Mohty M, Martino R, Faucher C, et al. Fludarabine and busulfan-based reduced intensity conditioning (RIC) allogeneic HLA-identical transplantation (allo-SCT) with or without anti-thymocyte globulin (ATG): Comparison between two prospective studies in patients with myeloid malignancies [abstract]. Blood 2004; 104:1241.
16. Martino R, Ho A, Sierra J, et al. Reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation with or without alemtuzumab in acute myelogenous leukaemia and myelodysplastic syndromes: Comparison between two prospective studies using fludarabine and oral busulphan [abstract]. Bone Marrow Transplant 2004; 33:O120.
17. Valcárcel D, Martino R, Martin J. Fludarabine-busulphan reduced intensity conditioning (RIC) Identical sibling allogeneic stem cell transplantation (Allo-SCT) in high-risk acute myeloid leukemia and myelodisplastic syndrome [abstract]. Biol Blood Marrow Transplant 2007; 13:134-135.
18. Blaise DP, Michel BJ, Faucher C, et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005; 104:1931-1938.
19. Martino R, Caballero MD, Simon JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100:2243-2245.
20. Van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23:5728-5738.
21. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387-9393.
22. Hamaki T, Kami M, Kim SW, et al. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. Bone Marrow Transplant 2004; 33:891-900.
23. Platzbecker U, Thiede C, Fussel M, et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 2006; 20:707-714. This single center trial showed that up-front allogeneic-HSCT with RIC after induction therapy, in newly diagnosed high risk patients seems effective.
24. Oran B, Giralt S, Saliba R, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2007; 13:454-462. This single center study showed the results of Flu-Melphalan RIC regimen in patients with AML/MDS with related and unrelated donors.
25. Grigg AP, Gibson J, Bardy PG, et al. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biol Blood Marrow Transplant 2007; 13:560-567. This multicenter prospective study showed the results of fludarabine-cyclophosphamide RIC regimen in patients with high risk AML in first line.
26. Schmid C, Schleuning M, Ledderose G, et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675-5687.
27. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108:1092-1099. This prospective study suggested that performing an RIC a few days after salvage Flu-HD ARA-C containing salvage chemotherapy may be feasible and reduces the risk of early relapse in high risk or refractory AML/MDS.
28. Lima de M, Giralt S, Caldera G, et al. Results of a phase I/II study of gemtuzumab ozogamicin added to fludarabine (F), melphalan (M) and allogeneic hematopoietic stem cell transplantation (HSCT) for relapsed myeloid leukemias [abstract]. Blood 2005; 106:841.
29. Soriano Andres O, Champlin RE, McCormic G, et al. Maintenance therapy with 5-azacitidina (5-AC) after allogeneic stem cell transplantation (Allo-SCT) for acute myelogenous leukemia (AML) and high risk myelodisplastic syndrome (MDS): a dose and schedule finding study [abstract]. Blood 2007; 108:3668.
30. Roman E, Cooney E, Militano O, et al. Reduced intensity conditioning allogeneic stem cell transplantation followed by targeted condolidation immunotherapy with gemtuzubam ozogamicin in children and adolescents with CD33+ acute myeloid leukemia [abstract]. Biol Blood Marrow Transplant 2007; 13:76.
31. Bethge A, Hegenbart U, Stuart M, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004; 103:790-795.
32. Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100:3108-3114.
33. Meyer R, Britten C, Wehler D, et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 2007; 109:374-382.